

Renal Cell Carcinoma / Melanoma

Reference Number: F4722
Date of Response: 22/08/2022

Further to your Freedom of Information Act request, please find the Trust's response, in **blue bold text** below:

Royal Devon's Eastern FOI Office Response

Q1. How many patients have been treated in the past 3 months (**Latest data includes February 2022 – April 2022**) with the following agents for renal cell carcinoma:

- Avelumab + Axitinib –* <5 patients
- Axinitib – (**Incorrect spelling changed to Axitinib**) – <5 patients
- Cabozantinib – **11 patients**
- Everolimus – **0 patients**
- Lenvatinib + Everolimus – **0 patients**
- Nivolumab – **8 patients**
- Nivolumab + Cabozantinib – **0 patients**
- Nivolumab + Ipilimumab – *<5 patients
- Pazopanib – *<5 patients
- Pembrolizumab monotherapy – **0 patients**
- Pembrolizumab + Axitinib – **0 patients**
- Pembrolizumab + Lenvatinib – **0 patients**
- Sunitinib – **11 patients**
- Temsirolimus – **0 patients**
- Tivozanib – **0 patients**
- Other active systemic anti-cancer therapy – **0 patients**

Q2. How many patients have been treated in the past 3 months (**Latest data includes February 2022 – April 2022**) with the following agents for melanoma (any stage):

- Cobimetinib – **0 patients**
- Dabrafenib – *<5 patients
- Dabrafenib AND Trametinib – **9 patients**
- Dacarbazine – **0 patients**
- Encorafenib AND Binimetinib – *<5 patients
- Ipilimumab – *<5 patients
- Ipilimumab AND Nivolumab – <5 patients
- Nivolumab – **10 patients**
- Pembrolizumab – **50 patients**
- Trametinib – **0 patients**
- Vemurafenib – **0 patients**
- Vemurafenib AND Cobimetinib – **0 patients**

- Other active systemic anti-cancer therapy – **Bleomycin electrochemotherapy** – * <5 patients,
- **Talimogene Laherparepvec** – * <5 patients
- Palliative care only – **0**

* ≤5. In accordance with section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles.